‘India Pharma Week’ Returns With a Week Full of Avant-garde Events Alongside CPhI and P-MEC India

21 November 2017, Mumbai : A distinguished assemblage of Leadership, Business, Knowledge, Networking, Recognition and Innovation in the Pharma domain by UBM India.

South Asia’s largest Pharma event

CPhI and P-MEC India to be held at two different venues i.e., MMRDA Grounds (BKC), Mumbai – 27th to 29th Nov; the Bombay Exhibition Centre (Goregaon) – 28th to 30th Nov

1500+ exhibitors; 40+ countries

More than 10 eclectic events across Mumbai throughout the India Pharma Week

UBM India, India’s leading B2B exhibition organizer, is all set to bring in the second edition of the widely appreciated India Pharma Week, a week-long celebration packed with avant-garde events from 25th to 30th November alongside its flagship expo CPhI and P-MEC India. In its 11th edition, the marquee expo will be held at two venues in Mumbai – MMRDA Grounds, Bandra Kurla Complex (27th to 29th November) and Bombay Exhibition Centre (28th to 30th November).

Celebrating 11 years of CPhI and P-MEC India, the India Pharma Week will organise more than 10 events and activities taking place across the city of Mumbai pertaining to the streams of business, knowledge, leadership, innovation, recognition and networking in the field of pharma. The week will commence with a Plant visit followed by a series of engagements such as Pharma Leaders Golf, Pre-Connect Congress, Women in Pharma – Power Breakfast, India Pharma Awards, Networking Evening, the CPhI & P-MEC India Exhibition, a closed-door CEO Roundtable and many more activities.

Incepted in 2006, the CPhI & P-MEC India exhibition has grown remarkably larger over the years with exhibitors and visitors engaging over significant levels of business. It has been approved and comprehensively assisted in its endeavours by governing bodies such as Pharmaceuticals Export Promotion Council (Pharmexcil). Spread across two locations, this year’s edition will see more than 1500 exhibitors and participation from over 40 countries.

Speaking on the announcement of the IPW, Mr. Yogesh Mudras, Managing Director, UBM India said, “I am delighted to announce the second edition of the week-long India Pharma Week, an unrivalled offering to the world of exhibitions along with the CPhI & P-MEC India, UBM’s flagship engagement platform, and the world’s leading pharmaceutical networking event. An epitome of India’s strength in the pharma industry, the expo has consistently grown to serve as an exclusive congregation of key global players across the pharmaceutical sector. Over the past few years, India is seen as a potential market for global pharmaceutical manufacturers and is now ready to transform into a global pharmacy hub. The various economic drivers and government policies like pharma parks, boosting the Biosimilars and biologics sector along with ancillary sectors, and reducing manufacturing costs are the key driving factors for the growth of the sector in the country. The ‘Pharma Vision 2020’ which was introduced to make India a global leader in end-to-end drug manufacturing has also boosted investments.”

“The India Pharma Week stems from the proactive role it plays in driving key Governmental initiatives such as ‘Make in India’, ‘Startup India, Stand Up India’, and ‘Skill India’ connecting the global community to eke out solutions to challenges, and establishing superior standards within it. With the recent proposal by the Drug Controller General of India (DCGI) to make it mandatory for all employees in pharmaceutical manufacturing facilities to get skill certification, a notable congregation of industry experts and knowledge sharing, such as IPW provides becomes even more significant,” he further added.

About the CPhI and P-MEC India Expo

Originating from CPhI Worldwide – CPhI India has become South Asia’s leading pharma meeting place covering every step of the supply chain from drug discovery to finished dosage, encompassing CROs, CMOs and manufacturers of API, Generics, Excipients and Drug Formulation, Fine Chemicals, Biosimilars, Finished Formulations, Lab Chemicals and Biotechnology.